Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5059158 | 1.00 | HSD17B10 (0.47) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL7039511 | 1.00 | HSD17B10 (0.47) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL3974583 | 1.00 | HSD17B10 (0.47) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL27329590 | 1.00 | HSD17B10 (0.47) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL29299517 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL18537917 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL18537936 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL22821626 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTSLC6A9MEN1LMNA | |
| SCHEMBL15831767 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTMEN1TSHRKMT2A | |
| SCHEMBL18537914 | 0.91 | HSD17B10 (0.40) | HSD17B10MAPTSLC6A9MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-1047677-B1 | Process for the preparation of derivatives of 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid | BRACCO SPA (IT) | 2005-07-20 | — | — | EP | disclosed |
| EP-0717639-B1 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CHELATOR LLC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0717639-A4 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0717639-A1 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD. (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5409689-A | MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms | CONCAT, LTD. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1995005118-A1 | POLYAMINO PARAMAGNETIC CHELATES WHICH CONTAIN BOTH PHOSPHONATE AND NON-PHOSPHONATE MOIETIES FOR MRI | CONCAT LTD. (US) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885MAPT 2444/4885SLC6A9 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.